Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY
(2023)
Journal Article
Pearce, F. A., Lim, S. H., Bythell, M., Lanyon, P., Hogg, R., Taylor, A., Powter, G., Cooke, G. S., Ward, H., Chilcot, J., Thomas, H., Mumford, L., McAdoo, S. P., Pettigrew, G. J., Lightstone, L., & Willicombe, M. (2023). Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY. The Lancet Rheumatology, 5(8), E461-E473. https://doi.org/10.1016/S2665-9913%2823%2900160-1
Background: In the UK, additional COVID-19 vaccine booster doses and treatments are offered to people who are immunosuppressed to protect against severe COVID-19, but how best to choose the individuals that receive these vaccine booster doses and tre... Read More about Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY.